Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, INTERPACE BIOSCIENCES, INC. reported revenue of $39M, down 17.5% year over year. Operating margin was 10.5% and net margin 63.5%, on a free-cash-flow margin of 14.1% with capital expenditure at 0.9% of revenue. Every figure is computed directly from IDXG's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $39M | 10.5% | 63.5% |
| FY2024 | $47M | 17.3% | 14.3% |
| FY2023 | $40M | 9.9% | 4.9% |
| FY2022 | $32M | -11.4% | -69.0% |
| FY2021 | $33M | -19.1% | -45.1% |
How does IDXG compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.